Clinical trials for lung cancer
129 currently recruiting clinical trials
If you are a doctor and would like find matching clinical trials for you patients, create an account or log in
If you are a patient and would like to know if you may participate in a clinical trial, please consult your doctor so that he can send your file to a matching trial
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
EGFR
Targeted therapy
Systemic Treatment-Naive
Janssen
Janssen
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
EGFR
None
Systemic Treatment-Naive
Janssen
Janssen
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Non-squamous NSCLC
Locally Advanced
EGFR
None
Chemotherapy
Radiotherapy
AstraZeneca
AstraZeneca
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Localized
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
PDL1 Positive (>= 50%)
None
Systemic Treatment-Naive
ALK
EGFR
Bristol-Myers Squibb
Bristol-Myers Squibb
Early Access
Lung cancer
SCLC (Small Cell Lung Cancer)
Localized
Locally Advanced
None
Chemotherapy
Radiotherapy
Chemotherapy
Radiotherapy
AstraZeneca
AstraZeneca
Phase 3
Lung cancer
#NCT06074588
NSCLC (Non-Small Cell Lung Cancer)
Non-squamous NSCLC
Locally Advanced
Metastatic
ALK
BRAF
EGFR
MET
NTRK-1/2/3
RET
ROS-1
Chemotherapy
Targeted therapy
Systemic Treatment-Naive
Antibody Drug Conjugates (ADC)
Institut Curie - Paris (Paris), Centre Hospitalier Universitaire de Rouen (Rouen), Centre Léon Bérard (Lyon), Institut Bergonié (Bordeaux)
Merck Sharp & Dohme LLC
Phase 3
Lung cancer
#NCT06561386
NSCLC (Non-Small Cell Lung Cancer)
Non-squamous NSCLC
Locally Advanced
Metastatic
NTRK-1/2/3
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
Systemic Treatment-Naive
ALK
BRAF
EGFR
ROS-1
Immunotherapy
Immunotherapy
Centre Hospitalier de la Côte Basque (Bayonne)
Bristol-Myers Squibb
Phase 3
Lung cancer
#NCT06216301
NSCLC (Non-Small Cell Lung Cancer)
Squamous NSCLC
Non-squamous NSCLC
Metastatic
None
Systemic Treatment-Naive
ALK
EGFR
MET
NTRK-1/2/3
RET
ROS-1
Institut Curie - Paris (Paris)
NovoCure GmbH
Phase 3
Lung cancer
#NCT06875310
NSCLC (Non-Small Cell Lung Cancer)
Non-squamous NSCLC
Locally Advanced
Metastatic
KRAS G12C
None
Systemic Treatment-Naive
Targeted therapy
Targeted therapy
CHRU de Nancy - Hôpitaux de Brabois (Vandœuvre-lès-Nancy), Centre Hospitalier Régional Et Universitaire CHRU de Brest (Brest), Hôpital Cochin (Paris ), Centre Jean Perrin (Clermont Ferrand ), Institut de Cancérologie de l'Ouest - Site de Saint-Herblain (Saint-Herblain)
Mirati Thérapeutique Inc.
Phase 3
Lung cancer
#NCT05920356
NSCLC (Non-Small Cell Lung Cancer)
Non-squamous NSCLC
Locally Advanced
Metastatic
KRAS G12C
PDL1 Negative (< 1%)
None
Systemic Treatment-Naive
Targeted therapy
Immunotherapy
Chemotherapy
Targeted therapy
Car-T
Bispecific T-cell engager antibodies
Antibody Drug Conjugates (ADC)
Centre Hospitalier de Cornouaille (Quimper), Centre Antoine Lacassagne (Nice), Institut de Cancérologie et d’Hématologie Universitaire de Saint-Étienne (CHU Saint-Étienne) (Saint-Priest-en-Jarez), Centre Hospitalier Universitaire de Lille - Institut Cœur Poumon (Lille), Centre Hospitalier Universitaire de Nîmes (Nîmes) (and 24 more...)
Amgen